32 results
Page 2 of 2
8-K
rm0h5a3yyhpo 60pf7w
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
8-K
EX-99.1
fw24d2
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
10-K
8ze7jhrh3xpg
25 Mar 21
Annual report
12:00am
10-Q
lhmiajgd7
20 Aug 20
Quarterly report
4:51pm
424B4
ci8oiw8
10 Jul 20
Prospectus supplement with pricing info
9:35pm
S-1/A
e7blraq9n9v1
2 Jul 20
IPO registration (amended)
5:17pm
S-1
cjcbfcm hl56lcrrzalc
19 Jun 20
IPO registration
3:24pm
DRS/A
p1e4tov7uyrrk90
19 May 20
Draft registration statement (amended)
12:00am
DRS/A
2lygwkrlg 3huyp
20 Apr 20
Draft registration statement (amended)
12:00am
DRS
h6ravlgzf
28 Feb 20
Draft registration statement
12:00am